New Prognostic Indicators in Pediatric Adrenal Tumors: Neuroblastoma and Adrenal Cortical Tumors, Can We Predict When These Will Behave Badly? Surg Pathol Clin 2020 Dec;13(4):625-641
Date
11/14/2020Pubmed ID
33183724DOI
10.1016/j.path.2020.08.002Scopus ID
2-s2.0-85092229346 (requires institutional sign-in at Scopus site) 5 CitationsAbstract
Pediatric adrenal tumors are unique entities with specific diagnostic, prognostic, and therapeutic challenges. The adrenal medulla gives rise to peripheral neuroblastic tumors (pNTs), pathologically defined by their architecture, stromal content, degree of differentiation, and mitotic-karyorrhectic index. Successful risk stratification of pNTs uses patient age, stage, tumor histology, and molecular/genetic aberrations. The adrenal cortex gives rise to adrenocortical tumors (ACTs), which present diagnostic and prognostic challenges. Histologic features that signify poor prognosis in adults can be meaningless in children, who have superior outcomes. The key clinical, pathologic, and molecular findings of pediatric ACTs have yet to be completely identified.
Author List
Jarzembowski JAAuthor
Jason A. Jarzembowski MD, PhD Sr Associate Dean, CEO CSG, Professor in the Pathology department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Adrenal Cortex NeoplasmsAge Factors
Biomarkers, Tumor
Humans
Immunohistochemistry
Mutation
Neoplasm Staging
Neuroblastoma
Prognosis
Tumor Suppressor Protein p53